Cytokinetics, Incorporated

As of June 30, 2026, Cytokinetics, Incorporated carries a market capitalization of 10.37B, placing it among publicly traded companies globally. Its enterprise value stands at 10.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cytokinetics, Incorporated's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Cytokinetics, Incorporated has 138.76M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 157.03, and the price-to-book ratio stands at -68.30.

These figures are as of June 30, 2026. The EV/Sales ratio of 176.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.46B versus a market cap of 10.37B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cytokinetics, Incorporated maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.36, indicating conservative leverage, while an interest coverage ratio of -5.57 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -56.76, reflecting losses generated across the asset base. The company generates approximately 94,130.39 in revenue per employee across its workforce of 629.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Cytokinetics, Incorporated's stock has gained approximately 19.40% over the past 52 weeks. The 50-day moving average sits at 60.45, while the 200-day moving average is 60.89.

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated generated 59.23M in revenue and converted that into -782.52M in net income, yielding earnings per share of -6.29. EBITDA reached -608.65M, while operating income came in at -619.63M.

As of June 30, 2026, Cytokinetics, Incorporated holds 1.02B in cash and equivalents against 1.11B in total debt, resulting in a net debt position of 780.61M. Total book value stands at -151.85M, with working capital of 898.98M providing operational flexibility.

Cytokinetics, Incorporated produced -486.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22.11M in capital expenditures, free cash flow totaled -508.30M - equivalent to -4.08 per share.

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated posted a gross margin of -212.95, reflecting its pricing power and cost economics. The operating margin of -1,046.12 and net profit margin of -1,321.12 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.48, meaning Cytokinetics, Incorporated raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cytokinetics, Incorporated's most recent stock split took place on June 25, 2013 with a 6:1 split ratio.

As of June 30, 2026, Cytokinetics, Incorporated has an Altman Z-Score of 0.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.